FREMONT, CA, July 06, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ:ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that the Zacks Small-Cap Research report dated June 7, 2022 values ABVC at $9.50 per share based upon a financial projection and a series of assumptions in the update.
Read more at globenewswire.comZacks Places Share Value of ABVC BioPharma at $9.50
Globe Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here